Enliven Therapeutics, Inc. 13D

OrbiMed reduced its stake in Enliven Therapeutics to about 9.5% following June 22, 2025 share sales, and states no activist intentions while retaining flexibility to trade the position.

On June 22, 2026, OrbiMed Advisors LLC, together with OrbiMed Capital GP VII LLC and OrbiMed Genesis GP LLC, filed Amendment No. 5 to their Schedule 13D on Enliven Therapeutics, Inc., disclosing beneficial ownership of an aggregate 6,774,507 common shares (approximately 9.5% of the 71,422,989 shares outstanding) held through OrbiMed Private Investments VII, LP and OrbiMed Genesis Master Fund, L.P.; the amendment reflects a reduction of more than 1% in their beneficial ownership following June 22, 2025 open-market sales and reiterates that they are passive, fundamental investors with no current plans for corporate or governance changes, while reserving flexibility to buy or sell shares based on market conditions and issuer performance.

Filing Facts

CIK

1672619

Ticker

ELVN

Form

13D

Source Type

sec

Accession

0000947871-26-000651

Alert Tier

7